Artanti Anif Nur, Jenie Riris Istighfari, Rumiyati Rumiyati-, Meiyanto Edy
Doctoral Programme in Pharmaceutical Science, Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara, Yogyakarta 55281, Indonesia.
Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada (UGM), Sekip Utara, Yogyakarta 55281, Indonesia.
Asian Pac J Cancer Prev. 2024 Dec 1;25(12):4247-4255. doi: 10.31557/APJCP.2024.25.12.4247.
Cisplatin (Cisp) is a chemotherapy drug for treating liver cancer. Hesperidin (HSD), a flavanone, is known for its anticancer, and anti-inflammatory properties. Diosmin (DSM), a flavone glycoside, is known for its anti-oxidant effect. This research investigated the synergism cytotoxic effect and senescence selectivity effect of HSD or DSM co-treatment with Cisp on HepG2 cells and Vero cells.
The cytotoxicity and cell viability of HSD or DSM combined with Cisp on HepG2 and Vero cells were assessed using the MTT assay with IC50 parameters, selectivity index (SI), and Combination Index (CI), while the antiproliferative profile was determined by colony-forming assay. Cellular senescence on HepG2 and Vero cell lines was determined using senescence-associated β-galactosidase (SA-β-gal) staining. Furthermore, the impact of apoptosis was evaluated using flowcitometry.
In the MTT assay, HSD, DSM, and cisplatin exhibited cytotoxic effects on HepG2 cells, with IC50 values of 321 µM, 148 µM, and 5 µM, respectively. Co-treatment with HSD and DSM with cisplatin enhanced cell sensitivity, resulting in a combination index of < 1. HSD and DSM exhibited minimal cytotoxicity against Vero cells, with IC50 values exceeding 500 µM. Both HSD and DSM reduced cellular senescence in Vero cells caused by cisplatin exposure. These findings suggest that co-treatment with HSD and DSM alongside cisplatin can synergistically lessen the viability of HepG2 cells. The Annexin V-FITC/PI apoptosis assay also showed more cells undergoing apoptosis in the co-treatment group. Both co-treatment HSD and DSM with Cisp independently induced the senescence of HepG2 cells and reduced the cellular senescence of normal kidney cells.
Consequently, both HSD and DSM show potential for development as co-treatment agents in combination with Cisp for hepatocellular carcinoma, and they may also be useful for reducing senescence in normal kidney cells.
顺铂(Cisp)是一种用于治疗肝癌的化疗药物。橙皮苷(HSD),一种黄烷酮,以其抗癌和抗炎特性而闻名。地奥司明(DSM),一种黄酮糖苷,以其抗氧化作用而闻名。本研究调查了HSD或DSM与Cisp联合处理对HepG2细胞和Vero细胞的协同细胞毒性作用和衰老选择性作用。
使用MTT法,通过IC50参数、选择性指数(SI)和联合指数(CI)评估HSD或DSM与Cisp联合对HepG2和Vero细胞的细胞毒性和细胞活力,同时通过集落形成试验确定抗增殖情况。使用衰老相关β-半乳糖苷酶(SA-β-gal)染色确定HepG2和Vero细胞系的细胞衰老。此外,使用流式细胞术评估凋亡的影响。
在MTT试验中,HSD、DSM和顺铂对HepG2细胞均表现出细胞毒性作用,IC50值分别为321µM、148µM和5µM。HSD和DSM与顺铂联合处理增强了细胞敏感性,联合指数<1。HSD和DSM对Vero细胞的细胞毒性最小,IC50值超过500µM。HSD和DSM均降低了顺铂暴露导致的Vero细胞中的细胞衰老。这些发现表明,HSD和DSM与顺铂联合处理可协同降低HepG2细胞的活力。Annexin V-FITC/PI凋亡试验还显示联合处理组中有更多细胞发生凋亡。HSD和DSM与Cisp联合处理均独立诱导HepG2细胞衰老并减少正常肾细胞的细胞衰老。
因此,HSD和DSM都有作为与Cisp联合治疗肝细胞癌的联合治疗药物开发的潜力,它们也可能有助于减少正常肾细胞的衰老。